Immix Biopharma To Present Milestones Achieved To Enable Kick-Off Of 2 IMX-110 Clinical Trials At 2022 ThinkEquity Conference On October 26
Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology